辛伐他汀改善子宫肌瘤细胞机械转导异常
该实验室研究从5例行子宫切除术患者的肌瘤组织分离原代细胞,用辛伐他汀0.001–1 μM处理48小时,发现其降低β1整合素蛋白44%、I型胶原60%,抑制黏着斑激酶磷酸化与RhoA活化,并减少凝胶收缩,提示辛伐他汀可能恢复肌瘤机械转导异常。
要点
- 辛伐他汀降低肌瘤细胞β1整合素蛋白44%、I型胶原60%。
- 辛伐他汀使黏着斑激酶磷酸化降至对照的26%–60%。
- 辛伐他汀减少RhoA活性45%–85%,凝胶面积增大122%–153%。
核心结论
- 辛伐他汀可能通过下调β1整合素下游机械信号通路,恢复子宫肌瘤细胞的机械转导异常状态。
研究设计与样本
- 实验室实验研究,原代肌瘤细胞来自5例行子宫切除术患者的组织,原代与永生化细胞用辛伐他汀0.001、0.01、0.1、1 μM或对照处理48小时。
主要发现
- 辛伐他汀使β1整合素蛋白表达降低44%、I型胶原降低60%。
- 辛伐他汀使黏着斑激酶磷酸化降至对照的26%–60%,总黏着斑激酶蛋白表达增加。
- 辛伐他汀使活性RhoA降低45%–85%,凝胶收缩减弱,凝胶面积较对照大122%–153%。
- 辛伐他汀降低AKAP13、ROCK1、肌球蛋白轻链激酶和cyclin D1等β1整合素下游机械信号蛋白水平。
临床怎么用
- 现有证据仅为体外细胞实验,提示辛伐他汀可能作为恢复肌瘤机械转导异常的治疗候选,尚需临床试验验证。
局限性
- 研究为实验室基础实验,原代细胞仅来自5例患者,尚未在临床人群中验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uterine leiomyomas, the most common tumors of the female reproductive system, are characterized by excessive deposition of disordered stiff extracellular matrix and fundamental alteration in the mechanical signaling pathways. Specifically, these alterations affect the normal dynamic state of responsiveness to mechanical cues in the extracellular environment. These mechanical cues are converted through integrins, cell membrane receptors, to biochemical signals including cytoskeletal signaling pathways to maintain mechanical homeostasis. Leiomyoma cells overexpress β1 integrin and other downstream mechanical signaling proteins. We previously reported that simvastatin, an antihyperlipidemic drug, has antileiomyoma effects through cellular, animal model, and epidemiologic studies. OBJECTIVE: This study aimed to examine the hypothesis that simvastatin might influence altered mechanotransduction in leiomyoma cells. STUDY DESIGN: This is a laboratory-based experimental study. Primary leiomyoma cells were isolated from 5 patients who underwent hysterectomy at the Department of Gynecology and Obstetrics of the Johns Hopkins University Hospital. Primary and immortalized human uterine leiomyoma cells were treated with simvastatin at increasing concentrations (0.001, 0.01, 0.1, and 1 μM, or control) for 48 hours. Protein and mRNA levels of β1 integrin and extracellular matrix components involved in mechanical signaling were quantified by quantitative real-time polymerase chain reaction, western blotting, and immunofluorescence. In addition, we examined the effect of simvastatin on the activity of Ras homolog family member A using pull-down assay and gel contraction. RESULTS: We found that simvastatin significantly reduced the protein expression of β1 integrin by 44% and type I collagen by 60% compared with untreated leiomyoma cells. Simvastatin-treated cells reduced phosphorylation of focal adhesion kinase down to 26%-60% of control, whereas it increased total focal adhesion kinase protein expression. Using a Ras homolog family member A pull-down activation assay, we observed reduced levels of active Ras homolog family member A in simvastatin-treated cells by 45%-85% compared with control. Consistent with impaired Ras homolog family member A activation, simvastatin treatment reduced tumor gel contraction where gel area was 122%-153% larger than control. Furthermore, simvastatin treatment led to reduced levels of mechanical signaling proteins involved in β1 integrin downstream signaling, such as A-kinase anchor protein 13, Rho-associated protein kinase 1, myosin light-chain kinase, and cyclin D1. CONCLUSION: The results of this study suggest a possible therapeutic role of simvastatin in restoring the altered state of mechanotransduction signaling in leiomyoma. Collectively, these findings are aligned with previous epidemiologic studies and other reports and support the need for clinical trials.
引用
- Afrin S, Islam MS, Patzkowsky K, et al. Simvastatin ameliorates altered mechanotransduction in uterine leiomyoma cells. Am J Obstet Gynecol. 2020. PMID: 32417359. doi:10.1016/j.ajog.2020.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。